Lung function after allogeneic hematopoietic stem cell transplant (HSCT) can be impaired by multiple factors including prior history of tobacco use, chemotherapy exposures, current or prior infections and chronic GvHD.
1,2
The alkylator busulfan (Bu), extensively utilized in conditioning regimens before HSCT, 3, 4 can cause acute lung injury, chronic interstitial fibrosis and alveolar hemorrhage which can lead to decreases in lung function as measured by diffusion capacity for carbon monoxide (DLCO), forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), FEV1/FVC ratio and total lung capacity (TLC). [5] [6] [7] Although pulmonary illness may lead to significant symptomatology, it is not known if asymptomatic patients have abnormal pulmonary function after HSCT. 8 On the other hand, although routine pulmonary function testing (PFT) by spirometry is recommended following transplantation in order to identify early signs of lung GvHD, 9, 10 few data exist to guide clinical decisions in those patients who do have a decrease in lung function in the absence of pulmonary symptoms. 2, [11] [12] [13] Among 63 consecutive patients who received a myeloablative HSCT conditioned with FluBu 3,4 at our institution between 2004 and 2010, 21 unselected patients (median age 45 years old; range 19-54 years old) who never presented with pulmonary symptoms and underwent routine PFTs after transplantation were retrospectively analyzed here. Study approval was obtained by the University of Illinois Institutional Review Board. Patients received a HSCT from a matched related donor (n = 12), or a matched unrelated donor (n = 7), or a one antigen mismatched unrelated donor (n = 2). Lung function score (LFS) was calculated per NIH recommendations based on FEV1 and DLCO: FEV1 and DLCO 480% = 1, 70-79% = 2, 60-69% = 3, 50-59% = 4, 40-49% = 5 and o40% = 6.
14 Based on LFS score, patients were divided into category 0 (LFS 2, normal), category 1 (LFS 3-5, mildly abnormal), category 2 (LFS 6-9, moderately abnormal) or category 3 (LFS 10-12, severely abnormal).
Median time of follow-up was 60 months (range 31-108 months). Patients had a diagnosis of AML or myelodysplastic syndrome (MDS) (n = 11), ALL (n = 3), CML (n = 3), NHL (n = 2) or CLL (n = 2) based on WHO classification. Out of eight patients with a history of tobacco use, seven had permanently ceased tobacco use before HSCT. The source of allogeneic hematopoietic stem cells was G-CSF mobilized PBSC (n = 18), bone marrow (n = 2) or cord blood (n = 1). To analyze whether asymptomatic patients would have a change in their pulmonary function after transplant, complete PFTs including corrected DLCO, FEV1, FVC, FEV1/FVC ratio and TLC were tested at our institution before and after HSCT. The results of the first posttransplant PFTs, performed at a median time of 14 months (range 3-31 months) (early PFTs), showed an overall decrease in the median of all lung function parameters although this decrease was not statistically different compared with pre-transplant results ( Figure 1a ). All these patients remained asymptomatic and underwent at least one further routine PFTs during posttransplant follow-up, at a median time of 48 months (range 12-102 months) (late PFTs). The results of late PFTs were then compared to early PFTs. Although average values of DLCO and TLC improved at the time of the second PFT, we observed a significant decline in FEV1 and FEV1/FVC results (P = 0.01 and 0.006, respectively) ( Figure 1b ). Although none of these patients had documented lung GvHD, we then tested whether the decline of PFTs could be associated with other manifestations of cGvHD. We compared the degree of change in DLCO, FEV1, FEV1/FVC ratio and TLC in 14 patients with extensive cGvHD with the remaining 7 with no cGvHD (Figure 1c) and no difference was observed.
Nevertheless, since 7 of 21 patients met NIH criteria for possible chronic lung GvHD based on decreased of FEV1 o75% of predicted normal and ratio of FEV1 to FVC o 0.7, they underwent further work up and in five of these patients a computed tomography scan of the lungs revealed abnormalities including interstitial and nodular airspace opacities, subpulmonic nodules and nodular ground glass opacities. In three of these patients, subsequent bronchoscopy with bronchoalveolar lavage and biopsy were not consistent with lung GvHD (Table 1) , nor infection. Only one of the seven patients had a prior history of tobacco use and this patient did not have a pre-transplant diagnosis of chronic obstructive pulmonary disease. As a result of this decline in PFTs, one patient was started on a bronchodilator. Moreover, no correlation was found between tobacco use or CMV reactivation, or with LFS category, or decline in FEV1 or FEV1/ FVC (data not shown). The 5 year overall survival for the cohort of 21 patients analyzed in this study was 86%. Of the 3 patients who died, causes of death were: relapse of leukemia in 2 cases, at 39 and 49 months, respectively; and septic shock in one patient at 34 months post transplant.
Our results show an overall decrease in all pulmonary function parameters in patients without apparent lung disease following a myeloablative Bu-based HSCT. In the initial post-transplant period, DLCO, FEV1, FEV1/FVC ratio and TLC were all decreased although differences did not reach statistical significance. During long-term follow-up, patients were noted to have some improvement in DLCO and TLC. However, FEV1 and FEV1/FVC continued to significantly decline though all patients continued to remain free of lung symptoms. These findings are similar to those of Bruno et al. 6 who reported a significant decrease in FEV1 and FVC in 22 pediatric patients conditioned with Bu at 2 years follow-up post HSCT, as well as Hildebrandt et al. 9 who also described a decrease in lung function in asymptomatic patients post HSCT suggesting that these changes may present much earlier than clinical symptoms of GvHD. There did not seem to be a correlation with decrease in lung function and tobacco history or CMV reactivation in our patient population. In our asymptomatic patient cohort, we could neither correlate the decrease of PFTs with clinical cGvHD nor with GvHD-associated radiological or histological findings.
The etiology of the decrease in pulmonary function parameters in this cohort remains not clear. Among different hypotheses, one could suggest that busulfan may lead to acute lung disease with multiple different manifestations. However, there is limited evidence of long-term decrease of lung function in patients conditioned with Bu and without lung symptoms. Lund et al. 5 did report a persistent decrease in DLCO 1 year post Bu-based HSCT in 34 patients without lung symptoms; however, unlike our patients, these patients showed improvement in FEV1 and FVC to baseline at 1 year. For this reason, we speculate that the decrease in lung function may be a manifestation of subclinical damage to the lung which may be due to Bu, or more likely to a GVH reaction that does not escalate to GvHD, or to the combination of these two factors.
Our results raise the potential of a high rate of significant asymptomatic lung dysfunction given that seven out of the cohort of 21 patients developed findings which warranted further investigation. The future implications in these patients are unknown as none have subsequently exhibited signs or symptoms of infection and none have developed lung GvHD on long-term follow-up. 
